Pediatricians Urge DEA to Reclassify Medical Marijuana to Boost Research
The American Academy of Pediatrics came out this week in favor of moving marijuana from Schedule 1, a category limited to drugs with no known or potential therapeutic effect, to Schedule 2. The change would make it easier to research the therapeutic effects of cannabis.
Seth Ammerman, a clinical professor in pediatrics at Stanford University and a member of the AAP national committee on substance abuse, co-authored the new policy statement. According to Ammerman, quoted in the Wall Street Journal (see the link below), “A Schedule 1 listing means there’s no medical use or helpful indications, but we know that’s not true because there has been limited evidence showing [marijuana] may be helpful for certain conditions in adults.”
“By placing this on Schedule 2,” says Ammerman, “it would allow the FDA to be involved [in pediatric research] as the agency is in any study. Unless scheduling changes, this won’t happen. And there could be therapeutic benefits. The AAP is not opposed to medical marijuana, per se, but we feel it’s important that this be explored within the [framework of the] FDA process, where you have standardization.”
Pure Green commends the AAP for taking this bold step. We look forward to the rescheduling of cannabis and the research into its therapeutic benefits that is sure to follow. For more information, click the link below or visit Pure Green, where we have a number of products, like high CBD tincture, for pediatric patients.